Drug Profile
Parnaparin sodium oral - Cosmo Pharmaceuticals
Alternative Names: CB-01-05; CB-01-05-MMX™; Extended-release parnaparin sodium; LMW Heparin MMX; Low molecular weight heparin oral - Cosmo PharmaceuticalsLatest Information Update: 26 Apr 2022
Price :
$50
*
At a glance
- Originator Cosmo Pharmaceuticals
- Class Anticoagulants; Low molecular weight heparins; Vascular disorder therapies
- Mechanism of Action Cytokine inhibitors; Interleukin 2 inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Ulcerative colitis
Most Recent Events
- 26 Apr 2022 Discontinued - Phase-II for Ulcerative colitis in Hungary (PO) (Cosmo Pharmaceuticals pipeline, April 2022)
- 26 Apr 2022 Discontinued - Phase-II for Ulcerative colitis in Italy (PO) (Cosmo Pharmaceuticals pipeline, April 2022)
- 26 Apr 2022 Discontinued - Phase-II for Ulcerative colitis in United Kingdom (PO) (Cosmo Pharmaceuticals pipeline, April 2022)